| Company Name: | QLT, Incorporated | | Ticker Symbol: | QLTI | | | WWW Address: | www.qltinc.com | | CEO: | Robert L. Butchofsky | | No. of Employees: | 135 | | Common Issue Type: | CS | | Business Description: | A global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 4.5 |  0.0 | 3.0 | 4.6 | 3.96 | 4.55 | 3.96 | 1941987 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 245.8 | 54.6 | 1.66 | 1.81 | 0.00 | 10.7 | 0.0 | 4.55 - 1.40 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 4.50 | $ | | PE Ratio - LTM | 10.7 | |
| Market Capitalisation | 245.8 | mil |
| Latest Shares Outstanding | 54.6 | mil |
| Earnings pS (EPS) | 1.81 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 919,556 | $ |
| Effective Tax Rate | 38.9 | % |
| Float | 54.2 | mil |
| Float as % of Shares Outstanding | 99.3 | % |
| Foreign Sales | 120 | mil |
| Domestic Sales | 5 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 17.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 22.70 | % |
| Gross Profit Margin | 37.5 | % |
| EBITDA Margin | -3.0 | % |
| Pre-Tax Profit Margin | 43.5 | % |
| Assets Turnover | 0.3 | % |
| Return on Assets (ROA) | 7.4 | % |
| Return on Equity (ROE) | 7.9 | % |
| Return on Capital Invested (ROCI) | 7.9 | % |
| Current Ratio | 13.9 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 16.3 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 4.84 | $ |
| Cash pS | 3.55 | $ |
| Book-Value pS | 5.74 | $ |
| Tangible Book-Value pS | 5.31 | $ |
| Cash Flow pS | 0.49 | $ |
| Free Cash Flow pS | -1.52 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.78 | |
| Price/Tangible Book Ratio | 0.85 | |
| Price/Cash Flow | 9.1 | |
| Price/Free Cash Flow | -3.0 | |
| P/E as % of Industry Group | 47.0 | % |
| P/E as % of Sector Segment | 8.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 22.0 | 120 | 4,439 | 22,892 |
| 4 Weeks | 4.55 | 3.34 | 3.49 | 28.9 | 120 | 3,873 | 69,707 |
| 13 Weeks | 4.55 | 3.17 | 4.24 | 6.1 | 98 | 4,486 | 278,121 |
| 26 Weeks | 4.55 | 2.01 | 2.27 | 98.2 | 164 | 4,364 | 549,821 |
| 52 Weeks | 4.55 | 1.40 | 1.90 | 136.8 | 191 | 4,388 | 1,097,110 |
| YTD | 4.55 | 1.40 | - | 86.7 | 152 | 3,972 | 905,549 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 3.91 | 3.86 | 3.75 | 3.23 | 2.84 | 1.66 | 1.83 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -10.43 | 71.5 | -11.57 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -40.45 | NA | -48.14 |
| R&D | -13.45 | NA | -23.76 |
| Normalized Inc. | -13.40 | NA | -3.26 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -14.2 | -19.2 | -2.9 |
| Earnings % | -85.4 | -93.9 | 0.0 |
| EPS % | -80.9 | -91.9 | 0.0 |
| EPS $ | -1.40 | -1.81 | 3.28 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 52.78 |
| Current Ratio | 2.8 |
| Quick Ratio (Acid Test) | 1.7 |
| Liquidity Ratio (Cash) | 2.00 |
| Receivables Turnover | 1.6 |
| Average Collection Period | 225 |
| Working Capital/Equity | 75.6 |
| Working Capital pS | 3.48 |
| Cash-Flow pS | 1.86 |
| Free Cash-Flow pS | -0.13 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.20 |
| Financial Leverage Ratio (Assets/Equity) | 1.4 |
| Debt Ratio | 30.2 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.0 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 3.4 |
| Interest/Capital Invested | 2.98 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.38 |
| Tobin's Q Ratio | 0.50 |
| Current P/E Ratio - LTM | 10.70 |
| Enterprise Value (EV)/EBITDA | 5.27 |
| Enterprise Value (EV)/Free Cash Flow | -8.36 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 0.85 |
| Price/Book Ratio - LTM | 0.78 |
| Price/Cash Flow Ratio | 9.1 |
| Price/Free Cash Flow Ratio - LTM | -3.0 |
| Price/Sales Ratio | 2.07 |
| P/E Ratio (1 month ago) - LTM | 8.4 |
| P/E Ratio (26 weeks ago) - LTM | 1.2 |
| P/E Ratio (52 weeks ago) - LTM | 1.7 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 47.0 |
| P/E as % of Sector Segment | 8.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 8.5 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 1.94 |
| Tangible Book Value pS - LTM | 5.31 |
| Book Value pS - LTM | 5.74 |
| Capital Invested pS | 6.28 |
| Cash pS - LTM | 3.55 |
| Cash Flow pS - LTM | 0.49 |
| Free Cash Flow pS - LTM | -1.52 |
| Earnings pS (EPS) | 1.81 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -7.71 |
| Free Cash Flow Margin 5YEAR AVG | -42.76 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | -69.5 |
| Equity Productivity | 0.36 |
| Return on Equity (ROE) | 39.3 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.36 |
| Return on Capital Invested (ROCI) | 39.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -21.0 |
| Assets Productivity | 0.20 |
| Return on Assets (ROA) | 27.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | -16.2 |
| Gross Profit Margin | 37.5 |
| Gross Profit Margin - 5YEAR AVRG. | 73.4 |
| EBITDA Margin - LTM | -3.0 |
| EBIT Margin - LTM | 46.3 |
| Pre-Tax Profit Margin | 19.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | -81.7 |
| Effective Tax Rate | 38.9 |
| Effective Tax Rate - 5YEAR AVRG. | 7.1 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 340 |
| Revenue per Employee | 919,556 |
| Net Income per Employee | 999,193 |
| Average Collection Period | 238 |
| Receivables Turnover | 1.6 |
| Day's Inventory Turnover Ratio | 102 |
| Inventory Turnover | 3.5 |
| Inventory/Sales | 9.4 |
| Accounts Payble/Sales | 7.34 |
| Assets/Revenue | 5.00 |
| Net Working Capital Turnover | 0.48 |
| Fixed Assets Turnover | 1.42 |
| Total Assets Turnover | 0.2 |
| Revenue per $ Cash | 0.75 |
| Revenue per $ Plant | 38.99 |
| Revenue per $ Common Equity | 0.36 |
| Revenue per $ Capital Invested | 0.36 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 17.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 15.9 |
| Research & Devlopment (R&D) as % of Revenue | 23.8 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 23.8 |
|
|  
|
| |
 |  |